Applied Genetic Technologies Corporation announced that Theresa Heah, M.D., Chief Medical Officer, has resigned from the company to pursue other opportunities. Given that the clinical results for the upcoming data releases are still being processed at external vendors and not yet available for internal review, Dr. Heah’s resignation does not relate to any knowledge of pending results. Dr. Heah has agreed to stay with the company until the end of the year to support the up-coming data analysis. The Company is exploring options to fill the role of CMO. In the interim, Dr. Matt Feinsod, M.D., who currently serves as Executive Vice President of Global Strategy and Development, and Dr. Nnenna Ihekoromadu, M.D., who recently joined the company as VP Clinical Research and Medical Affairs, will continue to provide medical oversight for the XLRP and ACHM clinical programs.